Spero Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $-45.4M | $10.3M |
| FY2017 | — | $84.6M | $87.3M |
| FY2018 | — | $115.5M | $34.1M |
| FY2019 | — | $74.6M | $29.7M |
| FY2020 | — | $132.0M | $85.2M |
| FY2021 | — | $88.3M | $112.6M |
| FY2022 | — | $75.9M | $109.1M |
| FY2023 | — | $106.9M | $76.3M |
| FY2024 | — | $46.1M | $52.9M |
| FY2025 | — | $59.0M | $40.3M |